Practical integration of ctDNA-defined minimal residual disease in gastrointestinal cancers: testing windows and evidence-aligned management frameworks
- 24 May 2026
- journal article
- review article
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (11) , 4996-5009
Abstract
Circulating tumor DNA (ctDNA) has emerged as a promising biomarker of minimal or molecular residual disease and real-time tumor burden in gastrointestinal cancers, but its clinical integration remains uneven across disease settings. This narrative review summarizes current evidence in colorectal, gastroesophageal, pancreatic, and biliary cancers, with emphasis on practical testing windows, assay selection, and evidence-aligned interpretation. The strongest data support ctDNA use in resected colon cancer, particularly stage II disease, where postoperative ctDNA refines recurrence risk assessment and has enabled treatment de-escalation in selected prospective settings. In rectal, upper gastrointestinal, pancreatic, and biliary cancers, current evidence is mainly prognostic and less practice-defining. Serial ctDNA may support postoperative risk stratification, surveillance prioritization, and trial selection, but treatment escalation or de-escalation should preferably remain within prospectively studied contexts. Key barriers include assay standardization, false-positive calls, turnaround time, reimbursement, and the need to distinguish prognostic validity from proven clinical utility.Keywords
This publication has 72 references indexed in Scilit:
- Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With CelecoxibJAMA Oncology, 2026
- Circulating tumor DNA as a predictive biomarker for colorectal cancer postsurgical recurrence: a systematic review and meta-analysisClinical and Translational Oncology, 2025
- Tumor‐agnostic detection of circulating tumor DNA in patients with advanced pancreatic cancer using targeted DNA methylation sequencing and cell‐free DNA fragmentomicsMolecular Oncology, 2025
- Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategyAnnals of Oncology, 2024
- Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage PlansJAMA Health Forum, 2024
- Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal CancerJAMA Network Open, 2024
- Circulating cell‐free DNA methylation‐based multi‐omics analysis allows early diagnosis of pancreatic ductal adenocarcinomaMolecular Oncology, 2024
- Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST)Annals of Oncology, 2023
- Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal CancerJAMA Oncology, 2019
- Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal CancerJAMA Oncology, 2019